Gastroenteritis - Pipeline Review, H1 2016
Summary
Global Markets Direct’s, ‘Gastroenteritis - Pipeline Review, H1 2016’, provides an overview of the Gastroenteritis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Gastroenteritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastroenteritis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Gastroenteritis
- The report reviews pipeline therapeutics for Gastroenteritis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Gastroenteritis therapeutics and enlists all their major and minor projects
- The report assesses Gastroenteritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Gastroenteritis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Gastroenteritis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gastroenteritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Gastroenteritis Overview 6
Therapeutics Development 7
Pipeline Products for Gastroenteritis – Overview 7
Pipeline Products for Gastroenteritis – Comparative Analysis 8
Gastroenteritis – Therapeutics under Development by Companies 9
Gastroenteritis – Therapeutics under Investigation by Universities/Institutes 11
Gastroenteritis – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Gastroenteritis – Products under Development by Companies 15
Gastroenteritis – Products under Investigation by Universities/Institutes 16
Gastroenteritis – Companies Involved in Therapeutics Development 17
Nanotherapeutics, Inc. 17
RedHill Biopharma Ltd. 18
Takeda Pharmaceutical Company Limited 19
UMN Pharma Inc. 20
Gastroenteritis – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Antibodies for Gastroenteritis - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
norovirus (bivalent) virus like particle vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ondansetron hydrochloride CR - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
TAK-214 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
UMN-2002 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
UMN-2003 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Gastroenteritis – Recent Pipeline Updates 37
Gastroenteritis – Product Development Milestones 43
Featured News & Press Releases 43
Mar 01, 2016: RedHill Biopharma Provides Update on RHB-102 43
Oct 14, 2015: RedHill Biopharma Provides Update on BEKINDA Ongoing Phase III Study for Gastroenteritis and Announces Planned Phase II Study for IBS-D 43
Mar 02, 2015: Positive Bioavailability Studies of RedHill's BEKINDA to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics Meeting 45
Dec 17, 2014: RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA) for Gastroenteritis and Gastritis 45
Dec 09, 2014: RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support 46
Sep 03, 2014: RedHill Biopharma Initiates Phase III Study of RHB-102 for Gastroenteritis 47
Dec 08, 2011: The New England Journal Of Medicine Publishes Study Showing LigoCyte's Norovirus Vaccine Demonstrates Protection Against Illness 48
Oct 25, 2010: LigoCyte Presents Positive Results From Norovirus Vaccine Challenge Study At IDSA Annual Meeting 50
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53
List Of Tables
List of Tables
Number of Products under Development for Gastroenteritis, H1 2016 7
Number of Products under Development for Gastroenteritis – Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Gastroenteritis – Pipeline by Nanotherapeutics, Inc., H1 2016 17
Gastroenteritis – Pipeline by RedHill Biopharma Ltd., H1 2016 18
Gastroenteritis – Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 19
Gastroenteritis – Pipeline by UMN Pharma Inc., H1 2016 20
Assessment by Monotherapy Products, H1 2016 21
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 27
Gastroenteritis Therapeutics – Recent Pipeline Updates, H1 2016 37
Lisst Of Figures
List of Figures
Number of Products under Development for Gastroenteritis, H1 2016 7
Number of Products under Development for Gastroenteritis – Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 14
Assessment by Monotherapy Products, H1 2016 21
Number of Products by Routes of Administration, H1 2016 24
Number of Products by Stage and Routes of Administration, H1 2016 24
Number of Products by Molecule Types, H1 2016 26
Number of Products by Stage and Molecule Types, H1 2016 26
